Preservative use in topical glaucoma medications

Ocular Surface

Volumn 9, Issue 3, 2011, Pages 140-158

  Tressler, Charles S ^a   Beatty, Richard ^b   Lemp, Michael A ^c  

^a PFIZER INC   (United States)

^b Physicians Regional Medical Group   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

Author keywords

BAC; BAK; Benzalkonium chloride; Bimatoprost; Brimonidine; Dorzolamide; Glaucoma; Latanoprost; Ocular hypertension; Preservative; Timolol; Travoprost

Indexed keywords

ADRENALIN; ADRENALIN BORATE; ANTIGLAUCOMA AGENT; APRACLONIDINE; BENZALKONIUM CHLORIDE; BETAXOLOL; BIMATOPROST; BIMATOPROST PLUS TIMOLOL; BRIMONIDINE; BRIMONIDINE PLUS TIMOLOL; BRINZOLAMIDE; CARBACHOL; CARTEOLOL; DEMECARIUM; DIPIVEFRINE; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; DORZOLAMIDE PLUS TIMOLOL MALEATE; ECOTHIOPATE; ESERINE SULPHATE; LATANOPROST; LATANOPROST PLUS TIMOLOL; LEVOBUNOLOL; LOPIDINE; METIPRANOLOL; OCUDOSE; OPTIRANOLOL; PHYSOSTIGMINE; PILOCARPINE; PRESERVATIVE; SAFLUTAN; TAFLUPROST; TIMOLOL; TIMOLOL MALEATE; TIMOLOL PLUS TRAVOPROST; TRAVOPROST; UNCLASSIFIED DRUG; UNOPROSTONE ISOPROPYL ESTER;

APOPTOSIS; CELL DAMAGE; CELL PROLIFERATION; CELL SIZE; CELL TYPE; CELL VIABILITY; CHROMOSOME CONDENSATION; CLINICAL TRIAL (TOPIC); CONJUNCTIVA; CORNEA; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; GLAUCOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LACRIMATION; META ANALYSIS (TOPIC); NONHUMAN; OXIDATIVE STRESS; PUNCTATE KERATITIS; REVIEW; TEAR FILM;

EID: 80051771373     PISSN: 15420124     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1542-0124(11)70024-6     Document Type: Review

References (209)

1. Novack GD, Evans R. Commercially available ocular hypotensive products: preservative concentration, stability, storage, and in-life utilization. J Glaucoma 2001;10:483-486 (Pubitemid 34001104)
2. Y ee RW. The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review. Curr Opin Ophthalmol 2007;18:134-139
3. Ocudose [timolol maleate ophthalmic solution] prescribing information. Available at: http://www.merck.com/product/usa/pi-circulars/t/ timoptic/timoptic-ocudose- pi.pdf. Accessed January 30, 2010
4. Trusopt [dorzolamide hydrochloride ophthalmic solution] prescribing information. Available at: http://www.merckfrosst.ca/assets/en/ pdf/products/TRU SOPT-1004-a-135834-E.pdf. Accessed May 7, 2010
5. Saflutan [tafluprost ophthalmic solution] prescribing information. Available at: http://www.emc.medicines.org.uk/medicine/22237/SPC/ SAFLU TAN+15+micrograms+ml+eye+drops%2c+solution%2c+sing le-%20dose+container/#PRODUC TINFO. Accessed January 30, 2010
6. C osopt [dorzolamide hydrochloride-timolol maleate ophthalmic solution] prescribing information. Available at: http://www.merckfrosst. ca/assets/en/pdf/products/COSOPT-1004- a-135835-E.pdf. Accessed May 7, 2010
7. C araccio TR, McGuigan MA. Benzalkonium chloride, in Dart RC (ed): Medical toxicology. New York, NY, Lippincott Williams & Wilkins, 2004, ed 3, pp 1255-1257
8. McCarey B, Edelhauser H. In vivo corneal epithelial permeability following treatment with prostaglandin analoges [sic] with or without benzalkonium chloride. J Ocul Pharmacol Ther 2007;23:445-451 (Pubitemid 350202478)
9. R yan G Jr, Fain JM, Lovelace C, Gelotte KM. Effectiveness of ophthalmic solution preservatives: a comparison of latanoprost with 0.02% benzalkonium chloride and travoprost with the sofZia preservative system. BMC Ophthalmol 2011;11:8. [E-pub ahead of print]
10. Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma 2002;11:119-126 (Pubitemid 34298592)
11. Whitson JT, Ochsner KI, Moster MR, et al. The safety and intraocular pressure-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1. Ophthalmology 2006;113:1333-1339 (Pubitemid 44108169)
12. Baudouin C, Labbé A, Liang H, et al. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res 2010;29:312-334
13. Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol 2008;86:716-726
14. Stewart WC, Stewart JA, Nelson LA . Ocular surface disease in patients with ocular hypertension and glaucoma. Curr Eye Res 2011;36:391-398
15. Mirza SK, Johnson SM. Efficacy and patient tolerability of travoprost BAK-free solution in patients with open-angle glaucoma and ocular hypertension. Clin Ophthalmol 2010;4:877-888
16. Yanochko GM, Khoh-Reiter S, Evans MG, Jessen BA. Comparison of preservative-induced toxicity on monolayer and stratified Chang conjunctival cells. Toxicol In Vitro 2010;24:1324-1331
17. Khoh-Reiter S, Jessen BA. Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model. BMC Ophthalmol 2009;9:5
18. Pauly A, Meloni M, Brignole-Baudouin F, et al. Multiple endpoint analysis of the 3D-reconstituted corneal epithelium after treatment with benzalkonium chloride: early detection of toxic damage. Invest Ophthalmol Vis Sci 2009;50:1644-1652
19. E pstein SP, Ahdoot M, Marcus E, Asbell PA. Comparative toxicity of preservatives on immortalized corneal and conjunctival epithelial cells. J Ocul Pharmacol Ther 2009;25:113-119
20. Dutot M, Liang H, Pauloin T, et al. Effects of toxic cellular stresses and divalent cations on the human P2X7 cell death receptor. Mol Vis 2008;14:889-897 (Pubitemid 351715810)
21. Buron N, Guery L, Creuzot-Garcher C, et al. Trefoil factor TFF 1-induced protection of conjunctival cells from apoptosis at premitochondrial and postmitochondrial levels. Invest Ophthalmol Vis Sci 2008;49:3790-3798
22. A yaki M, Yaguchi S, Iwasawa A, Koide R. Cytotoxicity of ophthalmic solutions with and without preservatives to human corneal endothelial cells, epithelial cells and conjunctival epithelial cells. Clin Exp Ophthalmol 2008;36:553-559
23. Brasnu E, Brignole-Baudouin F, Riancho L, et al. In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line. Curr Eye Res 2008;33:303-312 (Pubitemid 351507760)
24. Brasnu E, Brignole-Baudouin F, Riancho L, et al. Comparative study on the cytotoxic effects of benzalkonium chloride on the Wong-Kilbourne derivative of Chang conjunctival and IOBA-NHC cell lines. Mol Vis 2008;14:394-402 (Pubitemid 351377235)
25. Baudouin C, Riancho L, Warnet JM, Brignole F. In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost. Invest Ophthalmol Vis Sci 2007;48:4123-4128 (Pubitemid 351261038)
26. Pauly A, Brignole-Baudouin F, Guenoun JM, et al. Comparative study of topical anti-allergic eye drops on human conjunctiva-derived cells: responses to histamine and IFN gamma and toxicological profiles. Graefes Arch Clin Exp Ophthalmol 2007;245:534-546 (Pubitemid 46477314)
27. Sosne G, Albeiruti AR, Hollis B, et al. Thymosin β4 inhibits benzalkonium chloride-mediated apoptosis in corneal and conjunctival epithelial cells in vitro. Exp Eye Res 2006;83:502-507 (Pubitemid 44183802)
28. Y ee RW, Norcom EG, Zhao XC. Comparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture system. Adv Ther 2006;23:511-519
29. Dutot M, Pouzaud F, Larosche I, et al. Fluoroquinolone eye drop-induced cytotoxicity: role of preservative in P2X7 cell death receptor activation and apoptosis. Invest Ophthalmol Vis Sci 2006;47:2812-2819 (Pubitemid 351639751)
30. Buron N, Micheau O, Cathelin S, et al. Differential mechanisms of conjunctival cell death induction by ultraviolet irradiation and benzalkonium chloride. Invest Ophthalmol Vis Sci 2006;47:4221-4230 (Pubitemid 46579342)
31. C hung SH, Lee SK, Cristol SM, et al. Impact of short-term exposure of commercial eyedrops preserved with benzalkonium chloride on precorneal mucin. Mol Vis 2006;12:415-21
32. Guenoun JM, Baudouin C, Rat P, et al. In vitro comparison of cytoprotective and antioxidative effects of latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci 2005;46:4594-4599 (Pubitemid 44264559)
33. Guenoun JM, Baudouin C, Rat P, et al. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci 2005;46:2444-2450 (Pubitemid 43119492)
34. Pisella PJ, Debbasch C, Hamard P, et al. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci 2004;45:1360-1368 (Pubitemid 38859312)
35. H amard P, Blondin C, Debbasch C, et al. In vitro effects of preserved and unpreserved antiglaucoma drugs on apoptotic marker expression by human trabecular cells. Graefes Arch Clin Exp Ophthalmol 2003;241:1037- 43
36. Goto Y, Ibaraki N, Miyake K. Human lens epithelial cell damage and stimulation of their secretion of chemical mediators by benzalkonium chloride rather than latanoprost and timolol. Arch Ophthalmol 2003;121:835-839 (Pubitemid 36676221)
37. H uhtala A, Alajuuma P, Burgalassi S, et al. A collaborative evaluation of the cytotoxicity of two surfactants by using the human corneal epithelial cell line and the WST-1 test. J Ocul Pharmacol Ther 2003;19:11-21
38. Debbasch C, De La Salle SB, Brignole F, et al. Cytoprotective effects of hyaluronic acid and carbomer 934P in ocular surface epithelial cells. Invest Ophthalmol Vis Sci 2002;43:3409-3415 (Pubitemid 35334347)
39. H amard P, Debbasch C, Blondin C, et al. [Human trabecular cells and apoptosis: in vitro evaluation of the effect of betaxolol with or without preservative.] J Fr Ophtalmol 2002;25:777-84. French
40. H uhtala A, Mannerström M, Alajuuma P, et al. Comparison of an immortalized human corneal epithelial cell line and rabbit corneal epithelial cell culture in cytotoxicity testing. J Ocul Pharmacol Ther 2002;18:163-75
41. Debbasch C, Pisella PJ, Rat P, et al. [Antioxidant effects of mast cell inhibitors in a human conjunctival cell line.] J Fr Ophtalmol 2001;24:121-128French
42. De Saint Jean M, Debbasch C, Brignole F, et al. Relationship between in vitro toxicity of benzalkonium chloride (BAC) and preservative-induced dry eye. Adv Exp Med Biol 2002;506:697-702 (Pubitemid 36307738)
43. Debbasch C, Brignole F, Pisella PJ, et al. Quaternary ammoniums and other preservatives' contribution in oxidative stress and apoptosis on Chang conjunctival cells. Invest Ophthalmol Vis Sci 2001;42:642-652 (Pubitemid 32206903)
44. Burgalassi S, Chetoni P, Monti D, Saettone MF. Cytotoxicity of potential ocular permeation enhancers evaluated on rabbit and human corneal epithelial cell lines. Toxicol Lett 2001;122:1-8 (Pubitemid 32524053)
45. Debbasch C, Pisella PJ, De Saint Jean M, et al. Mitochondrial activity and glutathione injury in apoptosis induced by unpreserved and preserved beta-blockers on Chang conjunctival cells. Invest Ophthalmol Vis Sci 2001;42:2525-2533 (Pubitemid 32954858)
46. De Saint Jean M, Debbasch C, Brignole F, et al. Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells. Curr Eye Res 2000;20:85-94 (Pubitemid 30099159)
47. Debbasch C, De Saint Jean M, Pisella PJ, et al. [Quaternary ammonium cytotoxicity in a human conjunctival cell line.] J Fr Ophtalmol 1999;22:950-958French
48. De Saint Jean M, Brignole F, Bringuier AF, et al. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest Ophthalmol Vis Sci 1999;40:619-630 (Pubitemid 29109440)
49. Saarinen-Savolainen P, Järvinen T, Araki-Sasaki K, et al. Evaluation of cytotoxicity of various ophthalmic drugs, eye drop excipients and cyclodextrins in an immortalized human corneal epithelial cell line. Pharm Res 1998;15:1275-1280 (Pubitemid 28401721)
50. F riedlaender MH, Breshears D, Amoozgar B, et al. The dilution of benzalkonium chloride (BAK) in the tear film. Adv Ther 2006;23:835-41
51. Wu KY, Wang HZ, Hong SJ. Cellular cytotoxicity of antiglaucoma drugs in cultured corneal endothelial cells. Kaohsiung J Med Sci 2007;23:105-111
52. Wu KY, Hong SJ, Wang HZ. Effects of antiglaucoma drugs on calcium mobility in cultured corneal endothelial cells. Kaohsiung J Med Sci 2006;22:60-67
53. Burgalassi S, Monti D, Brignoccoli A, et al. Development of cultured rabbit corneal epithelium for drug permeation studies: a comparison with excised rabbit cornea. J Ocul Pharmacol Ther 2004;20:518-532 (Pubitemid 39628497)
54. Wu KY, Wang HZ, Hong SJ. Inhibition of endothelin-1 and KCl-induced increase of [Ca2+]i by antiglaucoma drugs in cultured A7r5 vascular smooth-muscle cells. J Ocul Pharmacol Ther 2004;20:201-209
55. H ong SJ, Wu KY, Wang HZ, Fong JC. Effects of commercial antiglaucoma drugs to glutamate-induced [Ca2+]i increase in cultured neuroblastoma cells. J Ocul Pharmacol Ther 2003;19:205-215
56. Goskonda VR, Hill RA, Khan MA, Reddy IK. Permeability of chemical delivery systems across rabbit corneal (SRC) cell line and isolated corneas: a comparative study. Pharm Dev Technol 2000;5:409-416 (Pubitemid 30602849)
57. Y u AL, Fuchshofer R, Kampik A, Welge-Lüssen U. Effects of oxidative stress in trabecular meshwork cells are reduced by prostaglandin analogues. Invest Ophthalmol Vis Sci 2008;49:4872-4880
58. Wu KY, Wang HZ, Hong SJ. Mechanism of unoprostone-induced cytosolic Ca2+mobility in cultured porcine corneal endothelial cells. Exp Eye Res 2007;85:185-191
59. Guo Y, Satpathy M, Wilson G, Srinivas SP. Benzalkonium chloride induces dephosphorylation of myosin light chain in cultured corneal epithelial cells. Invest Ophthalmol Vis Sci 2007;48:2001-2008 (Pubitemid 351261267)
60. Wu KY, Wang HZ, Hong SJ. Effects of antiglaucoma drugs on cellular proliferation in cultured human corneal keratocytes. Kaohsiung J Med Sci 2006;22:120-125
61. Wu KY, Wang HZ, Hong SJ. Effect of latanoprost on cultured porcine corneal stromal cells. Curr Eye Res 2005;30:871-879
62. Koh SW, Coll TJ, Rose L, et al. Antiglaucoma eye drop pulses-increased interleukin-6 secretion by Tenon's capsule fibroblast cultures. J Glaucoma 2004;13:200-209 (Pubitemid 38669070)
63. C ha SH, Lee JS, Oum BS, Kim CD. Corneal epithelial cellular dysfunction from benzalkonium chloride (BAC) in vitro. Clin Exp Ophthalmol 2004;32:180-184
64. C iviale C, Paladino G, Marino C, et al. Multilayer primary epithelial cell culture from bovine conjunctiva as a model for in vitro toxicity tests. Ophthalmic Res 2003;35:126-36
65. Ozdal PC, Deschênes J, Rudzinski M, et al. Chemotactic and chemokinetic properties of topical ophthalmic preparations. Curr Eye Res 2002;25:363-368 (Pubitemid 36724167)
66. Scholz M, Lin JE, Lee VH, Keipert S. Pilocarpine permeability across ocular tissues and cell cultures: influence of formulation parameters. J Ocul Pharmacol Ther 2002;18:455-468 (Pubitemid 37420254)
67. Stenton GR, Nohara O, Déry RE, et al. Proteinase-activated receptor (PAR) -1 and -2 agonists induce mediator release from mast cells by pathways distinct from PAR -1 and PAR -2. J Pharmacol Exp Ther 2002;302:466-474 (Pubitemid 34787208)
68. H endrix DV, Ward DA, Barnhill MA. Effects of anti-inflammatory drugs and preservatives on morphologic characteristics and migration of canine corneal epithelial cells in tissue culture. Vet Ophthalmol 2002;5:127-135
69. Wang YD, Kashiwagi K, Chen HB, et al. Effects of isopropyl unoprostone ophthalmic solution on cultured rabbit corneal epithelial cells. Ophthalmologica 2001;215:229-234 (Pubitemid 32525984)
70. Wang HZ, Hong SJ, Wu KY. Change of calcium and cAMP concentration by adrenoceptor agents in cultured porcine corneal endothelial cells. J Ocul Pharmacol Ther 2000;16:299-309
71. C hang SW, Chi RF, Wu CC, Su MJ. Benzalkonium chloride and gentamicin cause a leak in corneal epithelial cell membrane. Exp Eye Res 2000;71:3-10
72. Parnigotto PP, Bassani V, Montesi F, Conconi MT. Bovine corneal stroma and epithelium reconstructed in vitro: characterisation and response to surfactants. Eye 1998;12 (Pt 2):304-310 (Pubitemid 28263876)
73. Grant RL, Acosta D. Prolonged adverse effects of benzalkonium chloride and sodium dodecyl sulfate in a primary culture system of rabbit corneal epithelial cells. Fundam Appl Toxicol 1996;33:71-82
74. C unliffe IA, McIntyre CA, Rees RC, Rennie IG. The effect of topical cholinergic medications on human Tenon's capsule fibroblasts in tissue culture. Graefes Arch Clin Exp Ophthalmol 1995;233:507-512
75. C unliffe IA, McIntyre CA, Rees RC, Rennie IG. Pilot study on the effect of topical adrenergic medications on human Tenon's capsule fibroblasts in tissue culture. Br J Ophthalmol 1995;79:70-75
76. Kawa JE, Higginbotham EJ, Chang IL, Yue BY. Effects of antiglaucoma medications on bovine trabecular meshwork cells in vitro. Exp Eye Res 1993;57:557-565 (Pubitemid 23353091)
77. Williams DE, Nguyen KD, Shapourifar-Tehrani S, et al. Effects of timolol, betaxolol, and levobunolol on human Tenon's fibroblasts in tissue culture. Invest Ophthalmol Vis Sci 1992;33:2233-2241
78. Tripathi BJ, Tripathi RC, Kolli SP. Cytotoxicity of ophthalmic preservatives on human corneal epithelium. Lens Eye Toxic Res 1992;9:361-375 (Pubitemid 23111708)
79. Samples JR, Binder PS, Nayak S. The effect of epinephrine and benzalkonium chloride on cultured corneal endothelial and trabecular meshwork cells. Exp Eye Res 1989;49:1-12 (Pubitemid 19190148)
80. Neville R, Dennis P, Sens D, Crouch R. Preservative cytotoxicity to cultured corneal epithelial cells. Curr Eye Res 1986;5:367-372 (Pubitemid 16024350)
81. Majumdar S, Hippalgaonkar K, Repka MA. Effect of chitosan, benzalkonium chloride and ethylenediaminetetraacetic acid on permeation of acyclovir across isolated rabbit cornea. Int J Pharm 2008;348:175-178 (Pubitemid 350266247)
82. F rentz M, Goss M, Reim M, Schrage NF. Repeated exposure to benzalkonium chloride in the Ex Vivo Eye Irritation Test (EVEIT): observation of isolated corneal damage and healing. Altern Lab Anim 2008;36:25-32
83. Nakamura T, Yamada M, Teshima M, et al. Electrophysiological characterization of tight junctional pathway of rabbit cornea treated with ophthalmic ingredients. Biol Pharm Bull 2007;30:2360-2364 (Pubitemid 350223743)
84. Y oun HY, Moran KL, Oriowo OM, et al. Surfactant and UV-B-induced damage of the cultured bovine lens. Toxicol In Vitro 2004;18:841-52
85. C hetoni P, Burgalassi S, Monti D, Saettone MF. Ocular toxicity of some corneal penetration enhancers evaluated by electrophysiology measurements on isolated rabbit corneas. Toxicol In Vitro 2003;17:497-504
86. U bels JL, Paauw JD, Casterton PL, Kool DJ. A redesigned corneal holder for the bovine cornea opacity and permeability assay that maintains normal corneal morphology. Toxicol In Vitro 2002;16:621-628
87. van der Bijl P, van Eyk AD, Meyer D. Effects of three penetration enhancers on transcorneal permeation of cyclosporine. Cornea 2001;20:505-508 (Pubitemid 32565790)
88. Xu KP, Li XF, Yu FS. Corneal organ culture model for assessing epithelial responses to surfactants. Toxicol Sci 2000;58:306-314
89. Doughty MJ. Assessment of the effects of cetylpyridium chloride on water content of the collagen-keratocyte matrix of the mammalian corneal stroma ex vivo. Biochim Biophys Acta 1999;1426:449-458 (Pubitemid 29078560)
90. Burstein NL, Klyce SD. Electrophysiologic and morphologic effects of ophthalmic preparations on rabbit cornea epithelium. Invest Ophthalmol Vis Sci 1977;16:899-911 (Pubitemid 8201831)
91. Tonjum AM. Permeability of rabbit corneal epithelium to horseradish peroxidase after the influence of benzalkonium chloride. Acta Ophthalmol (Copenh) 1975;53:335-347
92. Tonjum AM. Effects of benzalkonium chloride upon the corneal epithelium studied with scanning electron microscopy. Acta Ophthalmol (Copenh) 1975;53:358-366
93. Green K, Tonjum AM. The effect of benzalkonium chloride on the electropotential of the rabbit cornea. Acta Ophthalmol (Copenh) 1975;53:348-357
94. Green K, Tonjum A. Influence of various agents on corneal permeability. Am J Ophthalmol 1971;72:897-905
95. Nguyen DH, Beuerman RW, DeWever B, Rosdy M. Three-dimensional construct of the human corneal epithelium for in vitro toxicology, in Salem H, Katz SA (eds): Alternative toxicological methods. Boca Raton, FL, CRC Press, 2003, pp 147-159
96. Van Goethem F, Adriaens E, Alépée N, et al. Prevalidation of a new in vitro reconstituted human cornea model to assess the eye irritating potential of chemicals. Toxicol In Vitro 2006:20:1-17 (Pubitemid 41796438)
97. Doucet O, Lanvin M, Thillou C, et al. Reconstituted human corneal epithelium: a new alternative to the Draize eye test for the assessment of the eye irritation potential of chemicals and cosmetic products. Toxicol In Vitro 2006;20:499-512
98. Patarca R, Rosenzwei JA, Zuniga AA, Fletcher MA. Benzalkonium salts: effects on G protein-mediated processes and surface membranes. Crit Rev Oncog 2000;11:255-305 (Pubitemid 32432911)
99. H enry JC, Peace JH, Stewart JA, Stewart WC. Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy. Clin Ophthalmol 2008;2:613-621
100. Townley R, Reilly C. Benzalkonium chloride (BAC) versus travoprost 0.004% without BAC . Dry eye and irritation comparison of latanoprost 0.005% with the preservative. Invest Ophthalmol Vis Sci 2009;50:E-Abstract 4651
101. Pauly A, Labbé A, Baudouin C, et al. In vivo confocal microscopic grading system for standardized corneal evaluation: application to toxic-induced damage in rat. Curr Eye Res 2008;33:826-838
102. Denoyer A, Ossant F, Arbeille B, et al. Very-high-frequency ultrasound corneal imaging as a new tool for early diagnosis of ocular surface toxicity in rabbits treated with a preserved glaucoma drug. Ophthalmic Res 2008;40:298-308
103. Kahook MY, Noecker R. Quantitative analysis of conjunctival goblet cells after chronic application of topical drops. Adv Ther 2008;25:743-751
104. Kahook MY, Noecker RJ. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea 2008;27:339-343 (Pubitemid 351440870)
105. L iang H, Baudouin C, Pauly A, Brignole-Baudouin F. Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride. Br J Ophthalmol 2008;92:1275-1282
106. L iang H, Brignole-Baudouin F, Rabinovich-Guilatt L, et al. Reduction of quaternary ammonium-induced ocular surface toxicity by emulsions: an in vivo study in rabbits. Mol Vis 2008;14:204-16
107. Xiong C, Chen D, Liu J, et al. A rabbit dry eye model induced by topical medication of a preservative benzalkonium chloride. Invest Ophthalmol Vis Sci 2008;49:1850-1856
108. H offman HM, Choi JH, Clousing DP, et al. Corneal epithelial testing strategies for safety evaluation of ophthalmic formulations. Cutan Ocul Toxicol 2007;26:311-27
109. Pauly A, Brignole-Baudouin F, Labbé A, et al. New tools for the evaluation of toxic ocular surface changes in the rat. Invest Ophthalmol Vis Sci 2007;48:5473-5483 (Pubitemid 351260847)
110. R uss HH, Costa VP, Ferreira FM, et al. Conjunctival changes induced by prostaglandin analogues and timolol maleate: a histomorphometric study. Arq Bras Oftalmol 2007;70:910-6
111. Okada Y. Effects of topical antiglaucoma medications on corneal epithelium as evaluated by gene expression patterns. Cornea 2007;26 (suppl 1):S46-S54 (Pubitemid 47442762)
112. U ematsu M, Kumagami T, Kusano M, et al. Acute corneal epithelial change after instillation of benzalkonium chloride evaluated using a newly developed in vivo corneal transepithelial electric resistance measurement method. Ophthalmic Res 2007;39:308-14
113. Kusano M, Uematsu M, Kumagami T, et al. Evaluation of acute corneal barrier change induced by topically applied preservatives using corneal transepithelial electric resistance in vivo. Cornea 2010;29:80-85
114. Whitson JT, Cavanagh HD, Lakshman N, Petroll WM. Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride. Adv Ther 2006;23:663-671 (Pubitemid 44955845)
115. L abbé A, Pauly A, Liang H, et al. Comparison of toxicological profiles of benzalkonium chloride and polyquaternium-1: an experimental study. J Ocul Pharmacol Ther 2006;22:267-78
116. Denoyer A, Ossant F, Arbeille B, et al. [In vivo assessment of corneal epithelial toxicity of timolol with benzalkonium chloride using veryhigh- frequency ultrasound imaging.] J Fr Ophtalmol 2006;29:11-18French
117. Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea 2004;23:490-496 (Pubitemid 38857008)
118. Kovoor TA, Kim AS, McCulley JP, et al. Evaluation of the corneal effects of topical ophthalmic fluoroquinolones using in vivo confocal microscopy. Eye Contact Lens 2004;30:90-94 (Pubitemid 43189030)
119. Kaufman HE, Varnell ED, Toshida H, et al. Effects of topical unoprostone and latanoprost on acute and recurrent herpetic keratitis in the rabbit. Am J Ophthalmol 2001;131:643-646 (Pubitemid 32422123)
120. F urrer P, Plazonnet B, Mayer JM, Gurny R. Application of in vivo confocal microscopy to the objective evaluation of ocular irritation induced by surfactants. Int J Pharm 2000;207:89-98
121. Pisella PJ, Fillacier K, Elena PP, et al. Comparison of the effects of preserved and unpreserved formulations of timolol on the ocular surface of albino rabbits. Ophthalmic Res 2000;32:3-8 (Pubitemid 30093503)
122. Baudouin C, Pisella PJ, Fillacier K, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology 1999;106:556-563 (Pubitemid 30191592)
123. Becquet F, Goldschild M, Moldovan MS, et al. Histopathological effects of topical ophthalmic preservatives on rat corneoconjunctival surface. Curr Eye Res 1998;17:419-425 (Pubitemid 28178417)
124. U bels JL, Woo EM, Watts WJ, et al. Conjunctival permeability and ultrastructure. Effects of benzalkonium chloride and artificial tears. Adv Exp Med Biol 1998;438:723-30
125. U bels JL, McCartney MD, Lantz WK, et al. Effects of preservative-free artificial tear solutions on corneal epithelial structure and function. Arch Ophthalmol 1995;113:371-8
126. Schaefer K, George MA, Abelson MB, Garofalo C. A scanning electron micrographic comparison of the effects of two preservative-free artificial tear solutions on the corneal epithelium as compared to a phosphate buffered saline and a 0.02% benzalkonium chloride control. Adv Exp Med Biol 1994;350:459-464 (Pubitemid 24130674)
127. Doughty MJ. Acute effects of chlorobutanol- or benzalkonium chloridecontaining artificial tears on the surface features of rabbit corneal epithelial cells. Optom Vis Sci 1994;71:562-572 (Pubitemid 24312131)
128. Mietz H, Niesen U, Krieglstein GK. The effect of preservatives and antiglaucomatous medication on the histopathology of the conjunctiva. Graefes Arch Clin Exp Ophthalmol 1994;232:561-565 (Pubitemid 24249226)
129. Berdy GJ, Abelson MB, Smith LM, George MA. Preservative-free artificial tear preparations. Assessment of corneal epithelial toxic effects. Arch Ophthalmol 1992;110:528-532
130. L ópez Bernal D, Ubels JL. Quantitative evaluation of the corneal epithelial barrier: effect of artificial tears and preservatives. Curr Eye Res 1991;10:645-656
131. L iu GS, Trope GE, Basu PK. Ultrastructural effects of topical Betoptic, Betagan, and Timoptic on the rabbit corneal endothelium. J Ocul Pharmacol 1989;5:329-342
132. C ollin HB. Ultrastructural changes to corneal stromal cells due to ophthalmic preservatives. Acta Ophthalmol (Copenh) 1986;64:72-78
133. Burstein NL. Preservative alteration of corneal permeability in humans and rabbits. Invest Ophthalmol Vis Sci 1984;25:1453-1457 (Pubitemid 15191102)
134. Dormans JA, van Logten MJ. The effects of ophthalmic preservatives on corneal epithelium of the rabbit: a scanning electron microscopical study. Toxicol Appl Pharmacol 1982;62:251-261 (Pubitemid 12185571)
135. Pfister RR, Burstein N. The effects of ophthalmic drugs, vehicles, and preservatives on corneal epithelium: a scanning electron microscope study. Invest Ophthalmol Vis Sci 1976;15:246-259
136. Wilson WS, Duncan AJ, Jay JL. Effect of benzalkonium chloride on the stability of the precorneal tear film in rabbit and man. Br J Ophthalmol 1975;59:667-669
137. R oggeband R, York M, Pericoi M, Braun W. Eye irritation responses in rabbit and man after single applications of equal volumes of undiluted model liquid detergent products. Food Chem Toxicol 2000;38:727-734
138. C urren RD, Harbell JW. In vitro alternatives for ocular irritation. Environ Health Perspect 1998;106 (suppl 2):485-492
139. Mishima S, Maurice DM. The oily layer of the tear film and evaporation from the corneal surface. Exp Eye Res 1961;1:39-45
140. H imebaugh NL, Begley CG, Bradley A, Wilkinson JA. Blinking and tear break-up during four visual tasks. Optom Vis Sci 2009;86:E106-E114
141. Maurice D. The effect of the low blink rate in rabbits on topical drug penetration. J Ocul Pharmacol Ther 1995;11:297-304
142. Jaenen N, Baudouin C, Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol 2007;17:341-349 (Pubitemid 47056287)
143. L eung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma 2008;17:350-355
144. Goldberg I, Li XY, Selaru P, Paggiarino D. A 5-year, randomized, open-label safety study of latanoprost and usual care in patients with open-angle glaucoma or ocular hypertension. Eur J Ophthalmol 2008;18:408-416
145. Vale J, Phillips CI. Practolol (Eraldin) eye drops as an ocular hypotensive agent. Br J Ophthalmol 1973;57:210-214
146. F elix RH, Ive FA, Dahl MGC. Cutaneous and ocular reactions to practolol. Br Med J 1974;4:321-324
147. Wright P. Untoward effects associated with practolol administration. Oculomucocutaneous syndrome. Br Med J 1975;1:595-598
148. Garner A, Rahi AH S. Practolol and ocular toxicity. Antibodies in serum and tears. Br J Ophthalmol 1976;60:684-686
149. R ahi AH S, Chapman CM, Garner A, et al. Pathology of practololinduced ocular toxicity. Br J Ophthalmol 1976;60:312-23
150. Zimmerman TJ, Boger WP 3rd. The beta-adrenergic blocking agents and the treatment of glaucoma. Surv Ophthalmol 1979;23:347-362 (Pubitemid 9199790)
151. A lm A, Schoenfelder J, McDermott J. A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma. Arch Ophthalmol 2004;122:957-965
152. Broadway DC, Grierson I, O'Brien C, Hitchings RA . Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch Ophthalmol 1994;112:1437-1445 (Pubitemid 24350506)
153. Broadway DC, Grierson I, O'Brien C, Hitchings RA . Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol 1994; 112:1446-1454 (Pubitemid 24350507)
154. H erreras JM, Pastor JC, Calonge M, Asensio VM. Ocular surface alteration after long-term treatment with an antiglaucomatous drug. Ophthalmology 1992;99:1082-1088
155. Y alvaç IS, Gedikoǧlu G, Karagöz Y, et al. Effects of antiglaucoma drugs on ocular surface. Acta Ophthalmol Scand 1995;73:246-8
156. Kuppens EV, de Jong CA, Stolwijk TR, et al. Effect of timolol with and without preservative on the basal tear turnover in glaucoma. Br J Ophthalmol 1995;79:339-342
157. Nuzzi R, Finazzo C, Cerruti A. Adverse effects of topical antiglaucomatous medications on the conjunctiva and the lachrymal (Brit. Engl) response. Int Ophthalmol 1998;22:31-35 (Pubitemid 29083233)
158. Inoue K, Okugawa K, Kato S, et al. Ocular factors relevant to anti-glaucomatous eyedrop-related keratoepitheliopathy. J Glaucoma 2003;12:480-485 (Pubitemid 37494176)
159. Baffa Ldo P, Ricardo JR, Dias AC, et al. Tear film and ocular surface alterations in chronic users of antiglaucoma medications. Arq Bras Oftalmol 2008;71:18-21
160. Martone G, Frezzotti P, Tosi GM, et al. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology (abstract). Am J Ophthalmol 2009;147:725-35;e1
161. H orsley MB, Kahook MY. Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients. Clin Ophthalmol 2009;3:291-295
162. Ishibashi T, Yokoi N, Kinoshita S. Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride. J Glaucoma 2003;12:486-490 (Pubitemid 37494177)
163. Manni G, Centofanti M, Oddone F, et al. Interleukin-1β tear concentration in glaucomatous and ocular hypertensive patients treated with preservative-free nonselective beta-blockers. Am J Ophthalmol 2005;139:72-77 (Pubitemid 40094842)
164. A lagöz G, Bayer A, Boran C, et al. Comparison of ocular surface side effects of topical travoprost and bimatoprost. Ophthalmologica 2008;222:161-7
165. Whitson JT, Trattler WB, Matossian C, et al. Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2010;26:287-292
166. Thygesen J, Aaen K, Theodorsen F, et al. Short-term effect of latanoprost and timolol eye drops on tear fluid and the ocular surface in patients with primary open-angle glaucoma and ocular hypertension. Acta Ophthalmol Scand 2000;78:37-44
167. Shimazaki J, Hanada K, Yagi Y, et al. Changes in ocular surface caused by antiglaucomatous eyedrops: prospective, randomised study for the comparison of 0.5% timolol v 0.12% unoprostone. Br J Ophthalmol 2000;84:1250-1254
168. C venkel B, Ihan A. Ocular surface changes induced by topical antiglaucoma monotherapy. Ophthalmologica 2002;216:175-179
169. Pisella PJ, Lala E, Parier V, et al. [Effect of preservatives on the conjunctiva: a comparative study of beta-blocker eye drops with and without preservatives in glaucoma patients.] J Fr Ophtalmol 2003;26:675-679French
170. Baudouin C, Hamard P, Liang H, et al. Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term. Ophthalmology 2004;111:2186-2192 (Pubitemid 39575587)
171. Baudouin C, Liang H, Hamard P, et al. The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways. Ophthalmology 2008;115:109-115
172. Malvitte L, Montange T, Vejux A, et al. Measurement of inflammatory cytokines by multicytokine assay in tears of patients with glaucoma topically treated with chronic drugs. Br J Ophthalmol 2007;91:29-32 (Pubitemid 46094003)
173. Kim CY, Hong S, Seong GJ. Brimonidine 0.2% versus brimonidine Purite 0.15% in Asian ocular hypertension. J Ocul Pharmacol Ther 2007;23:481-486 (Pubitemid 350202483)
174. Guglielminetti E, Barabino S, Monaco M, et al. HLA -DR expression in conjunctival cells after latanoprost. J Ocul Pharmacol Ther 2002;18:1-9 (Pubitemid 34132688)
175. C iancaglini M, Carpineto P, Agnifili L, et al. An in vivo confocal microscopy and impression cytology analysis of preserved and unpreserved levobunolol-induced conjunctival changes. Eur J Ophthalmol 2008;18:400-7
176. Moreno M, Villena A, Cabarga C, et al. Impression cytology of the conjunctival epithelium after antiglaucomatous treatment with latanoprost. Eur J Ophthalmol 2003;13:553-559 (Pubitemid 38208839)
177. Doǧan AS, Orhan M, Söylemezoǧlu F, et al. Effects of topical antiglaucoma drugs on apoptosis rates of conjunctival epithelial cells in glaucoma patients. Clin Exp Ophthalmol 2004;32:62-66 (Pubitemid 38344286)
178. Turaçli E, Budak K, Kaur A, et al. The effects of long-term topical glaucoma medication on conjunctival impression cytology. Int Ophthalmol 1997;21:27-33 (Pubitemid 27382075)
179. H ong S, Lee CS, Seo KY, et al. Effects of topical antiglaucoma application on conjunctival impression cytology specimens. Am J Ophthalmol 2006;142:185-6
180. de Jong C, Stolwijk T, Kuppens E, et al. Topical timolol with and without benzalkonium chloride: epithelial permeability and autofluorescence of the cornea in glaucoma. Graefes Arch Clin Exp Ophthalmol 1994;232:221-224 (Pubitemid 24127409)
181. L ass JH, Eriksson GL, Osterling L, et al. Comparison of the corneal effects of latanoprost, fixed combination latanoprost-timolol, and timolol: a double-masked, randomized, one-year study. Ophthalmology 2001;108:264-71
182. Sen E, Nalcacioglu P, Yazici A, et al. Comparison of the effects of latanoprost and bimatoprost on central corneal thickness. J Glaucoma 2008;17:398-402
183. Trocme S, Hwang LJ, Bean GW, Sultan MB. The role of benzalkonium chloride in the occurrence of punctate keratitis: a meta-analysis of randomized, controlled clinical trials. Ann Pharmacother 2010;44:1914-1921
184. Miyashiro MJ, Lo SC, Stewart JA, Stewart WC. Efficacy, safety and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients. Clin Ophthalmol 2010;23:1355-1359
185. L ewis RA, Katz GJ, Weiss MJ, et al; Travoprost BAC -free Study Group. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma 2007;16:98-103
186. C heng JW, Wei RL . Meta-analysis of 13 randomized controlled trials comparing bimatoprost with latanoprost in patients with elevated intraocular pressure. Clin Ther 2008;30:622-632
187. A lm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology 1995;102:1743-1752
188. C amras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology 1996;103:138-147
189. Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology 1996;103:126-137 (Pubitemid 26046169)
190. Mastropasqua L, Carpineto P, Ciancaglini M, Gallenga PE. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma. Ophthalmology 1999;106:550-555 (Pubitemid 30191591)
191. Pfeiffer N; European Latanoprost Fixed Combination Study Group. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol 2002;240:893-899
192. H igginbotham EJ, Feldman R, Stiles M, et al. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol 2002;120:915-22
193. DuBiner H, Cooke D, Dirks M, et al. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol 2001;45 (suppl 4):S353-S360
194. Gandolfi S, Simmons ST, Sturm R, et al. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther 2001;18:110-121 (Pubitemid 32852703)
195. Noecker RS, Dirks MS, Choplin NT, et al; Bimatoprost/Latanoprost Study Group. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 2003;135:55-63 (Pubitemid 36020425)
196. Parrish RK, Palmberg P, Sheu WP; XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003;135:688-703 (Pubitemid 36457976)
197. C ellini M, Caramazza R, Bonsanto D, et al. Prostaglandin analogs and blood-aqueous barrier integrity: a flare cell meter study. Ophthalmologica 2004;218:312-7
198. Walters TR, DuBiner HB, Carpenter SP, et al. 24-hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial. Surv Ophthalmol 2004;49 (suppl 1):S26-S35 (Pubitemid 38324612)
199. A rcieri ES, Santana A, Rocha FN, et al. Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial. Arch Ophthalmol 2005;123:186-92
200. Jin X, Qian S, Sun X. [Efficacy and safety of bimatoprost 0.03% in patients with elevated intraocular pressure: a comparison with latanoprost 0.005%.] Zhong-guo Shiyong Yan Ke Za Zhi 2005;23:712-714Chinese
201. Konstas AG, Katsimbris JM, Lallos N, et al. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. Ophthalmology 2005;112:262-266 (Pubitemid 40202562)
202. Orzalesi N, Rossetti L, Bottoli A, Fogagnolo P. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthalmology 2006;113:239-246 (Pubitemid 43170772)
203. H epsen IF, Ozkaya E. 24-h IOP control with latanoprost, travoprost, and bimatoprost in subjects with exfoliation syndrome and ocular hypertension. Eye (Lond) 2007;21:453-458
204. Konstas AG, Holló G, Irkec M, et al. Diurnal IOP control with bimatoprost versus latanoprost in exfoliative glaucoma: a crossover, observermasked, three-centre study. Br J Ophthalmol 2007;91:757-760 (Pubitemid 46846646)
205. Koz OG, Ozsoy A, Yarangumeli A, et al. Comparison of the effects of travoprost, latanoprost and bimatoprost on ocular circulation: a 6-month clinical trial. Acta Ophthalmol Scand 2007;85:838-843 (Pubitemid 350142805)
206. Katz G, Springs CL, Craven ER, Montecchi-Palmer M. Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost. Clin Ophthalmol 2010;4:1253-1261
207. A ihara M, Otani S-I, Kozaki J, et al. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost. J Glaucoma 2011. [E-pub ahead of print]
208. U ematsu M, Kumagami T, Shimoda K, et al. Influence of alkyl chain length of benzalkonium chloride on acute corneal epithelial toxicity. Cornea 2010;29:1296-301
209. L abbe A, Brasnu E, Van Went C, et al. Tear film osmolarity in patients treated for glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 2011;52:E-Abstract 218